Bridging the Gap: Enhancing Cancer Care for Underserved Populations With the Veris Health Cancer Care Platform

NCT07396064 | Not Yet Recruiting DMC

• 2 other identifiers: VER-PR-00235R44MD019611-02
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The proposed study aims to optimize and validate the Veris Cancer Care Platform for the needs of medically underserved cancer patients receiving outpatient cancer therapy. The Veris Health platform is a remote patient monitoring and communication system designed to bridge the gap between clinical visits and provide oncology care teams with objective data during high-risk periods. This study will specifically focus on optimizing the Veris Health platform for patients with language barriers, limited access to technology, and socioeconomic disparities. By incorporating user-centered design and working closely with community health centers, the research team will ensure that the platform is culturally and linguistically appropriate, easy to use, and accessible for all patients. The study will use a mixed-methods approach to validate the effectiveness of the optimized platform, including quantitative data analysis and qualitative interviews with patients and healthcare providers. The goal is to demonstrate the potential for the Veris Health platform to improve outcomes for vulnerable populations by reducing hospitalizations, emergency department visits, and the economic burden of cancer care.

Conditions

Cancer Care Recipient; Observational Study

Outcome Measures

Primary Outcomes (3)

• Usability of the Veris Health Cancer Care Platform

  Usability of the Veris Health Cancer Care platform as assessed by the Software Usability Measurement Inventory (SUMI) among patients, caretakers, and healthcare teams. Measure: SUMI total and domain scores Time Frame: During study participation

  5 Months

• Product Design Usability and Acceptability

  Ease of use, accessibility, and acceptability of the Veris Health Cancer Care platform based on A/B testing of product design features. Measure: Comparative usability metrics (e.g., task completion success, user preference) Time Frame: During study participation

  5 Months

• User Needs and Preferences

  User-identified needs, preferences, and barriers to use of the Veris Health Cancer Care platform. Measure: Qualitative themes derived from user interviews and focus groups Time Frame: During study participation

  5 Months

Secondary Outcomes (3)

• Health-Related Quality of Life (HRQL)

  5 Months

• Symptom Burden of Cancer Treatment Side Effects

  5 Months

• Cancer Treatment Adherence and Duration

  5 months

Study Arms (1)

Main Phase group

All participating subject utilizing the Veris Health app will complete all study health measurements with a 24 week period on the Veris Health app as well as participate in interviews and focus groups.

Other: Veris Health Inc. Application

Interventions

Veris Health Inc. Application OTHER

Veris Health offers at-home devices to monitor multiple physiological parameters, including temperature, heart rate, oxygen saturation, blood pressure, weight, and activity (step count). Patients are provided with a home cellular hub that is already paired to peripheral devices via Bluetooth. The hub communicates with all devices and the local cellular network out-of-the-box, and data is automatically sent via cellular network to the Veris Health backend database, making it easy for patients to use the system. Patients are responsible for taking their vital sign measurements daily. The devices automatically send the measurement data to the Veris Health HIPAA compliant, secure cloud server via the preconnected cellular hub.

Main Phase group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Underserved population undergoing Cancer treatment with at least one on the following barriers to healthcare access: Spanish as primary language, uninsured, insured with Medicaid, dual eligible for Medicare and Medicaid.

You may qualify if:

• Adults \> 18 years old
• Diagnosis of cancer
• ECOG Performance Status of 0-2
• Undergoing or initiating systemic anticancer therapy
• Able to utilize and interact with a mobile application and in-home devices for physiological monitoring. Have at least one of the following barriers to healthcare access: Spanish as primary language, uninsured, insured with Medicaid, dual eligible for Medicare and Medicaid

You may not qualify if:

• N/A

Sponsors & Collaborators

• National Institutes of Health (NIH): collaborator
• VERIS HEALTH INC: lead
• National Institute on Minority Health and Health Disparities (NIMHD): collaborator

Study Sites (1)

The Ohio State University

Columbus, Ohio, 43210, United States

Location

Related Links

• Related Info

Central Study Contacts

Brian deGuzman MD COO

CONTACT

917-813-1828; bjd@verishealth.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 5 Weeks
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 27, 2026
• First Posted: February 9, 2026
• Study Start: February 16, 2026
• Primary Completion: June 30, 2026
• Study Completion: June 30, 2026
• Last Updated: February 9, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)